e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Tuberculosis epidemiology and public health
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS)
N. Jain, N. Jain, M. Sharma, R. Aurangabadwalla, N. Joshi, J. Akanksha (Jaipur, India)
Source:
Annual Congress 2011 - Tuberculosis epidemiology and public health
Session:
Tuberculosis epidemiology and public health
Session type:
Thematic Poster Session
Number:
2645
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Jain, N. Jain, M. Sharma, R. Aurangabadwalla, N. Joshi, J. Akanksha (Jaipur, India). To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS). Eur Respir J 2011; 38: Suppl. 55, 2645
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients
Source: Annual Congress 2011 - Tuberculosis epidemiology and public health
Year: 2011
Treatment outcome and one year follow-up status of patients treated under DOTS category II
Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control
Year: 2008
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
DOT versus self administration in TB treatment in pilot area of sector 4, Bucharest- 3 years early re-treatment analysis
Source: Eur Respir J 2004; 24: Suppl. 48, 362s
Year: 2004
Outcome in DOTS category II patients by strengthening the regimen with daily levofloxacin
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years
Source: Eur Respir J 2004; 24: Suppl. 48, 653s
Year: 2004
Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Tuberculosis: follow-up of treatment without directed observed therapy (DOT) in a sanitary area
Source: Eur Respir J 2004; 24: Suppl. 48, 652s
Year: 2004
Outcomes of DOTS and DOTS Plus regimens implementing among patients with pulmonary tuberculosis relapses
Source: Eur Respir J 2002; 20: Suppl. 38, 369s
Year: 2002
Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Short 12-month regimen with intravenouse linezolid for MDR-TB: treatment outcomes and first follow up results.
Source: International Congress 2018 – New developments in tuberculosis
Year: 2018
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Impact of drug resistance among new cases on outcome of DOTS category I
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR)
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
DOTS PLUS versus non DOTS PLUS outcomes in MDRTB patients
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept